Integrative oncology along with systemic cancer therapies in advanced bladder and prostate cancer: metabolic optimization guiding the shift from palliative care to clinical remission – a case report - Takeaways - MDSpire

Integrative oncology along with systemic cancer therapies in advanced bladder and prostate cancer: metabolic optimization guiding the shift from palliative care to clinical remission – a case report

  • By

  • Pradeep M. K. Nair

  • Ayyappan Palanisamy

  • Sivaranjani Sekar

  • Shanmugam Sudarshan

  • Elangovan Karthika

  • Muniappan Devibala

  • Maruthanayagam Saranya

  • Thangavelu Ramasamy

  • Manickam Mahalingam

  • May 18, 2026

  • 0 min

Share

  • 1

    A 75-year-old male with advanced bladder cancer transitioned from palliative care to integrative oncology after chemotherapy intolerance.

  • 2

    The integrative oncology protocol included metabolic therapies, oncothermia, high-dose vitamin C, and lifestyle interventions.

  • 3

    The patient showed significant symptomatic relief, normalization of biomarkers, and stable metabolic activity on PET-CT within six months.

  • 4

    Quality of life improved substantially, and prognostic indices indicated enhanced survival potential following integrative treatment.

  • 5

    The findings suggest that combining systemic therapies with integrative approaches may improve outcomes in advanced bladder cancer.

Original Source(s)

Integrative oncology along with systemic cancer therapies in advanced bladder and prostate cancer: metabolic optimization guiding the shift from palliative care to clinical remission – a case report

  • by Pradeep M. K. Nair, Ayyappan Palanisamy, Sivaranjani Sekar, Shanmugam Sudarshan, Elangovan Karthika, Muniappan Devibala, Maruthanayagam Saranya, Thangavelu Ramasamy, Manickam Mahalingam

  • May 18, 2026

Related Content

Stimuli-responsive nanoplatforms for sonodynamic immunotherapy: opportunities and challenges in cancer treatment

VANGL1 links angiogenesis–stemness programs and tumor microenvironment remodeling: a pan-cancer, multi-omics study with translational validation

Use of PCSK9 Inhibitors Among Patients Receiving Immune Checkpoint Inhibitors for Cancer